Dreyfus Andrew 4

What Happened

• Andrew Dreyfus, a director of Alto Neuroscience, was granted 10,958 derivative securities (an option award) on 2026-05-12. The grant price reported is $0.00, meaning the award was issued at no cost to the director. This is a compensation grant (award), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-12; Form 4 filed: 2026-05-14 (timely filing).
• Transaction type/code: A (Award/Grant) — derivative security (option) for 10,958 shares at $0.00.
• Shares owned after transaction: Not disclosed in the filing.
• Notable footnotes:
  • Vesting: The underlying shares vest on the earlier of the one-year anniversary of the grant or the issuer’s next annual meeting, subject to continuous service (Footnote F1).
  • Compensation policy: The option was issued under the Issuer’s Non-Employee Director Compensation Policy and was not purchased by the reporting person (Footnote F2).

Context

• This is a routine director compensation award, common for non-employee directors; it does not involve an immediate exercise or sale. Because the award vests over time, any potential economic value depends on future vesting and the company’s stock price at that time.